SeqLL specializes in advanced sequencing technologies, particularly its proprietary True Single Molecule Sequencing (tSMS). This innovative approach allows for the direct parallel sequencing of millions of individual DNA and RNA molecules without the need for library preparation or amplification. By detecting nucleotide incorporation events on single strands, tSMS significantly reduces errors and biases commonly associated with traditional sequencing methods. This capability enables accurate analysis of low quantities of genetic material, including fragmented samples, making it particularly valuable for applications in molecular biology, such as RNA quantification and genomic studies.

In addition to tSMS, SeqLL offers a range of sequencing services that cater to various applications, including Direct RNA Sequencing (DRS) and methods for analyzing different types of RNA, such as non-coding RNA and circulating tumor cells. The technology is designed to address the challenges of quantifying gene expression and understanding complex biological processes. By providing high-quality sequencing solutions, SeqLL aims to facilitate research breakthroughs in personalized medicine and genomic therapies, thereby enhancing the understanding of genetic information and its implications in health and disease.

United States

SeqLL is a biotechnology company that specializes in Quantitative RNA & Specialty DNA Sequencing, offering True Single Molecule Sequencing technology.

SeqLL

Company Details